K.U. Dactinomycin

K.U. Dactinomycin Uses, Dosage, Side Effects, Food Interaction and all others data.

A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)

Generally, the actinomycins exert an inhibitory effect on gram-positive and gram-negative bacteria and on some fungi. However, the toxic properties of the actinomycins (including dactinomycin) in relation to antibacterial activity are such as to preclude their use as antibiotics in the treatment of infectious diseases. Because the actinomycins are cytotoxic, they have an antineoplastic effect which has been demonstrated in experimental animals with various types of tumor implant. This cytotoxic action is the basis for their use in the treatment of certain types of cancer. K.U. Dactinomycin is believed to produce its cytotoxic effects by binding DNA and inhibiting RNA synthesis.

K.U. Dactinomycin
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	K.U. Dactinomycin
Availability	Prescription only
Generic	Dactinomycin
Dactinomycin Other Names	ActD, Actinomycin C1, Actinomycin D, Actinomycin IV, Dactinomicina, Dactinomycin, Dactinomycine, Dactinomycinum, Meractinomycin
Related Drugs	aspirin, prednisone, ibuprofen, meloxicam, naproxen, Cymbalta, methotrexate, carboplatin, fluorouracil, doxorubicin
Type
Formula	C₆₂H₈₆N₁₂O₁₆
Weight	Average: 1255.417 Monoisotopic: 1254.628474764
Protein binding	5%
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	Brazil
Last Updated:	September 19, 2023 at 7:00 am

Uses

K.U. Dactinomycin is an actinomycin used to treat a wide variety of cancers.

For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen

K.U. Dactinomycin is also used to associated treatment for these conditions: Ewing's Sarcoma, Gestational Trophoblastic Disease, Ovarian Cancer, Rhabdomyosarcomas, Sarcoma, Osteogenic, Wilms' tumor, Metastatic nonseminomatous Testicular cancer

How K.U. Dactinomycin works

Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA (prevention of RNA polymerase elongation) and, consequently, with protein synthesis.